



DEPARTMENT OF HEALTH & HUMAN SERVICES

PUBLIC HEALTH SERVICE
NATIONAL INSTITUTES OF HEALTH

FOR US POSTAL SERVICE DELIVERY:

Office of Laboratory Animal Welfare
6700B Rockledge Drive, Suite 2500, MSC 6910
Bethesda, Maryland 20892-6910
Home Page: <http://grants.nih.gov/grants/olaw/olaw.htm>

FOR EXPRESS MAIL:

Office of Laboratory Animal Welfare
6700B Rockledge Drive, Suite 2500
Bethesda, Maryland 20817
Telephone: (301) 496-7163
Facsimile: (301) 402-7065

January 31, 2020

Re: Animal Welfare Assurance
#A4107-01 (OLAW Case 1X)

Dr. Daniel T. Jaffe
Vice President for Research
University of Texas at Austin
P.O. Box 7996
Austin, TX 78713

Dear Dr. Jaffe,

The Office of Laboratory Animal Welfare (OLAW) acknowledges receipt of your January 13, 2020 letter reporting an instance of noncompliance with the PHS Policy on Humane Care and Use of Laboratory Animals at the University of Texas at Austin, following up on an initial report on October 30, 2019. According to the information provided, OLAW understands that post-operative mice exhibited signs of pain after receiving over diluted analgesic. Miscommunication between laboratory staff and a technician led to this issue.

The corrective actions consisted of the veterinarian retraining the laboratory staff, developing an instruction sheet describing how to make analgesic dilutions, and recording solution concentration, dosage, and animal body weight. The records will be routinely reviewed by veterinary staff.

Based on its assessment of this explanation, OLAW understands that measures have been implemented to prevent recurrence of this problem. OLAW concurs with the actions taken by the institution to comply with the PHS Policy.

Sincerely,

(b) (6)

Axel Wolff, M.S., D.V.M.
Deputy Director
Office of Laboratory Animal Welfare

cc: IACUC Chair



THE UNIVERSITY OF TEXAS AT AUSTIN
The Office of the Vice President for Research

P.O. Box 7996 • FAC 426, G1400 • AUSTIN, TX 78713-7996 • 512-471-2877 • FAX 512-471-2827

January 13, 2020

Director, Division of Compliance Oversight
Office of Laboratory Animal Welfare
National Institutes of Health
RKL 1, Suite 360, MSC 7982
6705 Rockledge Drive
Bethesda, MD 20892-7982

Subject: Report of Non-Compliance with PHS Policy on Humane Care and Use of Laboratory Animals

To Whom It May Concern:

The University of Texas at Austin (UT), Animal Welfare Assurance #A4107-01, submits this report in compliance with section IV.F.3 of the PHS Policy on Humane Care and Use of Laboratory Animals and with the published guidance document NOT-OD-05-034 "Guidance on Prompt Reporting to OLAW under the PHS Policy on Humane Care and Use of Laboratory Animals." This letter is to report non-compliance that jeopardized animal health or welfare. The initial report was made on October 30, 2019.

A clinical veterinarian reviewed an investigator's post-operative records and noted that some mice that had recently undergone surgery showed indications of pain. After reviewing analgesic plans with the investigators, it was noted that these mice were administered over-diluted Carprofen after surgical procedures. The IACUC formed a subcommittee to further investigate this occurrence and the veterinarians worked closely with the investigators to refine analgesia. This issue arose from a miscommunication between experienced laboratory personnel and a new laboratory technician who was assigned responsibility for creating the diluted cocktail.

In order to prevent reoccurrence of this deficiency, multiple plans for correction were implemented. A clinical veterinarian retrained protocol personnel on how to create proper dilutions with Carprofen. The principal investigator also created an instructional sheet for protocol personnel that properly describes how to create analgesic dilutions. The investigators are documenting the solution concentrate as well as dosage given and animal weight on operative logs. Veterinary staff are performing regular laboratory visits to review these records.

The project involved in this report is funded by the following NIH project: 5R01EY028657-02, entitled "Cone Integration in the Visual Cortex". The grant officer has been copied on this notification.

Director, Division of Compliance Oversight
January 13, 2020
Re: PHS Assurance Number A4107-01
Page 2

Sincerely,

(b) (6)

Daniel T. Jaffe
Vice President for Research
University of Texas at Austin

DTJ:cim

cc: Kathryn Bayne, Global Director, AAALAC
S. John Mihic, Chair, Institutional Animal Care and Use Committee
Martha Flanders, Program Official, NIH

(b) (6)

Wolff, Axel (NIH/OD) [E]

From: OLAW Division of Compliance Oversight (NIH/OD)
Sent: Friday, January 24, 2020 7:27 AM
To: IACUC
Cc: OLAW Division of Compliance Oversight (NIH/OD)
Subject: RE: Final report of noncompliance- Assurance A4107-01

Thank you for this report, (b) (6) We will send a response soon.

Axel Wolff, M.S., D.V.M.
Deputy Director, OLAW

From: IACUC <IACUC@austin.utexas.edu>
Sent: Thursday, January 23, 2020 12:25 PM
To: OLAW Division of Compliance Oversight (NIH/OD) <olawdco@od.nih.gov>
Cc: IACUC <IACUC@austin.utexas.edu>; (b) (6) Mihic, S J <mihic@austin.utexas.edu>;
(b) (6) Jaffe, Dan <dtj@austin.utexas.edu>; Flanders, Martha (NIH/NEI) [E]
<martha.flanders@nih.gov>
Subject: Final report of noncompliance- Assurance A4107-01

Good morning,

On behalf of Dr. Daniel Jaffe, Vice President for Research at the University of Texas at Austin, please find attached the final report involving noncompliance with NIH grant award 5R01EY028657-02. The initial report was made October 30, 2019. Please let me know if you have any questions.

Thank you,

(b) (6)

14107-1X

Morse, Brent (NIH/OD) [E]

From: OLAW Division of Compliance Oversight (NIH/OD)
Sent: Wednesday, October 30, 2019 11:00 AM
To: IACUC; OLAW Division of Compliance Oversight (NIH/OD)
Cc: Jaffe, Dan; (b) (6) Mihic, S J; (b) (6)
Subject: RE: Initial report of noncompliance

Thank you for providing this preliminary report (b) (6) We will open a case file and await further information.

Best regards, Brent Morse

Brent C. Morse, DVM, DACLAM
Director
Division of Compliance Oversight
Office of Laboratory Animal Welfare
National Institutes of Health

Please note that this message and any of its attachments are intended for the named recipient(s) only and may contain confidential, protected or privileged information that should not be distributed to unauthorized individuals. If you have received this message in error, please contact the sender.

From: IACUC [mailto:IACUC@austin.utexas.edu]
Sent: Wednesday, October 30, 2019 10:11 AM
To: OLAW Division of Compliance Oversight (NIH/OD) <olawdco@od.nih.gov>
Cc: Jaffe, Dan <dtj@austin.utexas.edu>; (b) (6) Mihic, S J
<mihic@austin.utexas.edu>; (b) (6)
IACUC <IACUC@austin.utexas.edu>
Subject: Initial report of noncompliance

Director, Division of Compliance Oversight
Office of Laboratory Animal Welfare
National Institutes of Health
Rockledge 1, Suite 360, MSC 7982
6705 Rockledge Drive
Bethesda, MD 20892-7982

To Whom It May Concern,

On behalf of Dr. Daniel Jaffe, VP of Research, please accept this initial report of non-compliance for NIH project number 5R01EY028657-02, under Assurance number A4107-01.

A clinical veterinarian reviewed an investigator's post-operative records and noted that some animals that had recently undergone surgery showed indications of pain. After reviewing analgesic plans with the investigators, it was noted that these mice were administered over-diluted Carprofen after surgical procedures. The IACUC formed a subcommittee to further investigate this occurrence and the veterinarians are working closely with the investigators to ensure proper analgesia doses are used in mice.

As per NOT-OD-05-034, conditions that jeopardize the health or well-being of animals are reportable.

The IACUC will continue to review the matter. After finishing the review, a final report of its conclusions and actions will be submitted to the Office of Laboratory Animal Welfare. In the meantime, please let me know if you have any questions.

Sincerely,

(b) (6)